Background: Cutaneous leishmaniasis (CL) usually has a well clinical presentation that rarely confused with other dermatological diseases, but when it presents with atypical picture, it may be a diagnostic challenge to dermatologist. Objective: To record the cases of CL those have very unusual presentations or sites in the Iraqi patients that might be confused with other dermatoses. Patient and methods: This is a clinical descriptive study that has been performed in the outpatient of Department of Dermatology Baghdad Teaching Hospital, Baghdad, Iraq, during the period from January 2015-February 2017, where fifty six patients were enrolled in the study. The age of the patients ranged from 1-67 years old with median is 30 years, 32 males and 24 females with M:F ratio is 1.3:1, the diagnosis was confirmed by skin smear and/or biopsy. Results: Fifty six cases of CL with atypical presentations and unusual sites that categorized as follow: diffuse nodular 4 cases, paronychia like 1 case, sausage-like CL 4 cases, lupus vulgaris like 2 cases, rosacea like 1case, squamous cell carcinoma-like 3 cases, keratoacanthoma like 1 case, pyoderma gangrenosum-like 2 cases, erysipeloid like 1 case, B-cell lymphoma like 1 case, grouping pattern 1 case, panniculitis-like 2 cases, dermatitis like 2 cases, ecthyma like 1 cases, verruca like 1 case, keloid like 1 case, CL on the scalp 1 case, palmer CL 1 case, CL on the eyelid 1 case, CL on the ear 1 case, CL on the lips 3 cases, one genital CL case and twenty cases of sporotrichosis like spread. Conclusion: Unusual presentations of the CL with atypical lesions should be well recognized and investigated to confirm the diagnosis so that not to be confused with other skin diseases especially in countries where cutaneous leishmaniasis is not endemic disease.
Background: Zinc sulphate as intralesional and oral therapy was used as a successful therapy in treatment of cutaneous leishmaniasis while 25% topical podophyllin is now commonly used in the treatment of cutaneous leishmaniasis. Objective: To treat acute cutaneous leishmaniasis using topical zinc sulphate solution 25% to be compared with topical podophyllin solution 25%.Patients and Methods: This is a single, blind, interventional, comparative study done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, Iraq during the period from January 2015 to June 2015. Forty patients with a total 88 lesions of acute cutaneous leishmaniasis were enrolled in this study; 54 (61.36%) were dry lesions and 34 (38.6%) were ulcerative type. The duration of lesions ranged from 2 -11 (7.7 + 2.483) weeks. The size of the lesions ranged from 0.3 to 8 (2.13 ± 1.53) cm. There were 21 females and 19 males, female to male ratio (1.1:1) and their ages ranged from 1 to 60 (25.92 ± 16.59) years. Diagnosis was confirmed by tissue smear and histopathology. Lesions were divided into two groups with matching types and sizes, and scored according to Sharquie modified Leishmania score to assess the objective response to the topical or systemic therapy and then during follow up responses were graded into mild, moderate, marked response and complete clearance. Group A treated with topical 25% podophyllin solution once weekly for a maximum of 6 weeks, while group B was treated with topical 25% zinc sulphate solution twice daily for 6 weeks. Follow up was every 2 weeks during therapy, and once monthly for 3 months after therapy. Results: A total of 40 patients with clinical diagnosis of acute cutaneous leishmaniasis were included in this study, with a total of 88 lesions. Fifteen (37.50%) patients had Conclusion: Topical zinc sulphate 25% is an effective simple non-invasive non-costly safe topical therapy for cutaneous leishmaniasis and without any contraindications for its use and free of side effects and was as effective as topical podophyllin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.